Neoadjuvant
Animals
Apoptosis
B7-H1 Antigen
/ antagonists & inhibitors
Basic-Leucine Zipper Transcription Factors
/ physiology
Breast Neoplasms
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Proliferation
Combined Modality Therapy
Dendritic Cells
/ immunology
Female
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunomodulation
Immunotherapy
Lung Neoplasms
/ immunology
Mastectomy
Membrane Proteins
/ administration & dosage
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Mice, Nude
Neoadjuvant Therapy
/ methods
Radiotherapy
Repressor Proteins
/ physiology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
26
03
2021
revised:
21
09
2021
accepted:
14
10
2021
pubmed:
21
10
2021
medline:
7
1
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Neoadjuvant immunotherapy, given before surgical resection, is a promising approach to develop systemic antitumor immunity for the treatment of high-risk resectable disease. Here, using syngeneic and orthotopic mouse models of triple-negative breast cancer, we have tested the hypothesis that generation of tumor-specific T-cell responses by induction and activation of tumor-residing Batf3-dependent conventional type 1 dendritic cells (cDC1) before resection improves control of distant metastatic disease and survival. Mice bearing highly metastatic orthotopic tumors were treated with a combinatorial
Identifiants
pubmed: 34666993
pii: 0008-5472.CAN-21-0939
doi: 10.1158/0008-5472.CAN-21-0939
pmc: PMC8678344
mid: NIHMS1751659
doi:
Substances chimiques
B7-H1 Antigen
0
Basic-Leucine Zipper Transcription Factors
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Membrane Proteins
0
Repressor Proteins
0
SNFT protein, mouse
0
flt3 ligand protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6183-6195Subventions
Organisme : NCI NIH HHS
ID : K08 CA197966
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236390
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255240
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Nat Med. 2019 May;25(5):814-824
pubmed: 30962585
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Blood. 2014 Nov 13;124(20):3081-91
pubmed: 25100743
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
PLoS One. 2015 Nov 23;10(11):e0143370
pubmed: 26599402
J Immunother Cancer. 2021 May;9(5):
pubmed: 34049930
Clin Cancer Res. 2020 Oct 1;26(19):5068-5077
pubmed: 32434852
Cancer Res. 2018 Jan 15;78(2):475-488
pubmed: 29180478
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Clin Cancer Res. 2020 Jul 1;26(13):3091-3099
pubmed: 32071116
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Science. 2020 Jan 31;367(6477):
pubmed: 32001626
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Cancer Res. 2016 Oct 15;76(20):5994-6005
pubmed: 27550452
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
Cancer Res. 2012 Jul 1;72(13):3163-74
pubmed: 22570253
Cancer Immunol Res. 2018 Feb;6(2):139-150
pubmed: 29180535
Cancer Res. 2012 Nov 15;72(22):5721-32
pubmed: 22986739
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Nat Commun. 2020 Oct 27;11(1):5415
pubmed: 33110069
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33028691
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Cancer Res. 2011 Apr 1;71(7):2488-96
pubmed: 21300764
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
J Immunol. 2021 Sep 1;207(5):1298-1309
pubmed: 34362833
Lancet Oncol. 2015 Jul;16(7):795-803
pubmed: 26095785
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
J Clin Oncol. 2018 Jun 1;36(16):1611-1618
pubmed: 29437535
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751
pubmed: 31040150
Cancer Res. 2010 Apr 1;70(7):2697-706
pubmed: 20215523
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Science. 2018 Mar 23;359(6382):1403-1407
pubmed: 29567713
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9730-5
pubmed: 8790399
Nature. 2004 Jan 22;427(6972):355-60
pubmed: 14737169
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
J Immunol. 2004 Aug 1;173(3):2143-50
pubmed: 15265951
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Cancer Res. 1997 Apr 15;57(8):1597-604
pubmed: 9108466
Clin Cancer Res. 2021 Feb 1;27(3):665-679
pubmed: 32943460
J Immunol. 2005 Jun 15;174(12):7516-23
pubmed: 15944250
J Immunol. 2020 Oct 1;205(7):1867-1877
pubmed: 32848036